These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21692101)

  • 1. The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study.
    Mansouri A; Hadjibabaie M; Iravani M; Shamshiri AR; Hayatshahi A; Javadi MR; Khoee SH; Alimoghaddam K; Ghavamzadeh A
    Hematol Oncol; 2012 Mar; 30(1):22-6. PubMed ID: 21692101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: a double-blind randomized clinical trial.
    Arbabi-kalati F; Arbabi-kalati F; Deghatipour M; Ansari Moghadam A
    Arch Iran Med; 2012 Jul; 15(7):413-7. PubMed ID: 22724877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.
    Legert KG; Remberger M; Ringdén O; Heimdahl A; Dahllöf G
    Support Care Cancer; 2014 Aug; 22(8):2133-40. PubMed ID: 24647488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
    Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
    N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
    Freytes CO; Ratanatharathorn V; Taylor C; Abboud C; Chesser N; Restrepo A; Arango J; Odenheimer D
    Clin Cancer Res; 2004 Dec; 10(24):8318-24. PubMed ID: 15623608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation.
    Kim KI; Kim JW; Lee HJ; Kim BS; Bang SM; Kim I; Oh JM; Yoon SS; Lee JS; Park S; Kim BK
    Am J Hematol; 2013 Feb; 88(2):107-12. PubMed ID: 23225026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients.
    Sangthawan D; Phungrassami T; Sinkitjarurnchai W
    J Med Assoc Thai; 2013 Jan; 96(1):69-76. PubMed ID: 23720981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
    Heli U; Eeva J; Anne N; Tapani R; Liisa V
    Eur J Haematol; 2012 Jan; 88(1):87-8. PubMed ID: 22103782
    [No Abstract]   [Full Text] [Related]  

  • 11. Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.
    Busemann C; Wilfert H; Neumann T; Kiefer T; Dölken G; Krüger WH
    Onkologie; 2011; 34(10):518-24. PubMed ID: 21985850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
    Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
    J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation.
    Elad S; Ackerstein A; Bitan M; Shapira MY; Resnick I; Gesundheit B; Cohen Y; Diss O; Barak D; Dray L; Or R
    Bone Marrow Transplant; 2006 Apr; 37(8):757-62. PubMed ID: 16518424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.
    Vokurka S; Steinerova K; Karas M; Koza V
    Bone Marrow Transplant; 2009 Nov; 44(9):601-5. PubMed ID: 19349956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytopenia and hematopoietic recovery after low intensity conditioning transplants.
    Kostova G; Heim D; Passweg J; Buser A; Tichelli A; Gratwohl A
    Croat Med J; 2004 Aug; 45(4):445-50. PubMed ID: 15311417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
    Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation.
    Pielichowski W; Gawronski K; Mlot B; Oborska S; Wasko-Grabowska A; Rzepecki P
    J BUON; 2011; 16(3):541-6. PubMed ID: 22006763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.